Nippon Chemiphar : First Quarter Business Summary FY2022. (pdf,316KB)

（TSE 4539）

FY2022 First Quarter Business Summary

(Year Ending March 31, 2023)

Sales, Income

									(¥mn)
			FY2021				FY2022
		1Q	Distrib.	Year	1Q	Distrib.	YOY	Full Year	Progress
		Amount	(%)	Amount	Amount	(%)	(%)	(Forecast)	Rate (%)
Net sales	7,575	100.0	32,506	8,425	100.0	11.2	35,000	24.1
Pharmaceuticals	7,377	97.4	31,501	8,214	97.5	11.3	―	―
Generics, proprietary products and new drugs	6,569	86.7	28,037	7,129	84.6	8.5	29,000	24.6
Diagnostics	462	6.1	2,163	601	7.1	30.1	3,120	19.3
Others		197	2.6	1,004	210	2.5	6.6	―	―
Cost of sales		5,529	73.0	23,432	6,200	73.6	12.1	―	―
SG&A expenses	2,071	27.3	8,248	2,050	24.3	(1.0)	―	―
R&D expenses		620	8.2	2,392	445	5.3	(28.2)	3,000	14.9
Operating profit/loss		(26)	―	825	175	2.1	―	300	58.4
Ordinary profit	15	0.2	1,022	514	6.1	ｘ33	500	102.8
Net profit/loss attributable to
owners of the parent		(13)	―	700	653	7.8	―	550	118.7

1

Pharmaceutical Sales

Generics, Proprietary Products and New Drugs							(¥mn)
			FY2021				FY2022
		1Q	Distrib.	Year	1Q	Distrib.	YOY	Full Year	Progress
		Amount	(%)	Amount	Amount	(%)	(%)		(Forecast)	Rate (%)
Total	6,569	100.0	28,037	7,129	100.0	8.5		29,000	24.6
Generics	6,111	93.0	26,283	6,772	95.0	10.8		27,440	24.7
To medical institutions	5,817		25,043	6,524		12.2		26,600	24.5
To other makers*	294		1,239	247		(16.2)		840	29.4
Proprietary products	457	7.0	1,754	357	5.0	(21.9)		1,560	22.9
	Uralyt	156		623	149		(4.3)		580	25.8
	Others	301		1,131	208		(31.0)		980	21.2
Chemiphar, ODM Generics									(¥mn)
			FY2021				FY2022
		1Q	Distrib.	Year	1Q	Distrib.	YOY	Full Year	Progress
		Amount	(%)	Amount	Amount	(%)	(%)		(Forecast)	Rate (%)
Total	6,337	100.0	27,139	7,135	100.0	12.6		28,450	25.1
Generics	6,111	96.4	26,283	6,772	94.9	10.8		27,440	24.7
Generics (ODM)	226	3.6	856	363	5.1	60.9		1,010	36.0

* Includes exports.

2

Sales Distribution

By Launch Year					(¥mn)
	FY2021		FY2022
	1Q	Distrib.	1Q	Distrib.	YOY
	Amount	(%)	Amount	(%)	(%)
FY2015 and before	4,987	81.6	5,411	79.9	8.5
FY2016	137	2.2	174	2.6	27.4
FY2017	368	6.0	410	6.1	11.2
FY2018	189	3.1	224	3.3	18.7
FY2019	32	0.5	35	0.5	7.6
FY2020	337	5.5	361	5.3	7.1
FY2021	59	1.0	110	1.6	88.0
FY2022	―	―	43	0.6	―
Total	6,111	100.0	6,772	100.0	10.8

By Main Therapeutic Categories			(%)
		FY2021		FY2022
		1Q		1Q
Cardiovascular and respiratory drugs		28.3		27.5
Agents affecting metabolism		15.4		17.0
Digestive organ drugs		15.6		15.1
Drugs for nervous system, sensory organs		13.0		13.8
Antibiotics and chemotherapeutic drugs		6.5		4.6
Antineoplastic agents		2.5		1.9
Others		18.7		20.1

3

Balance Sheet, per Share Information

Balance Sheet Data					(¥mn)
		March 31, 2022		June 30, 2022
		Amount		Amount	Change
Total assets	49,453		51,402	1,948
Net assets	18,501	18,610	108
Owned capital	18,484	18,593	108
Capital-to-asset ratio (%)	37.4		36.2	(1.2)
Current assets		33,495		35,926	2,430
Current liabilities	16,750	16,572	(177)
Current ratio (x)	2.00		2.17	0.17

Per Share Information					(¥)
	FY2021		FY2022
	1Q	Full Year	1Q		Full Year
	Amount	Amount	Amount	YOY	(Forecast)
Earnings per share	(3.66)	194.33	180.91	―	152.50
					Full Year
	June 30, 2021	March 31, 2022	June 30, 2022		(Forecast)
Book value per share	4,976.70	5,119.99	5,150.78	174.08	―
Dividends per share	―	50.00	―	―	50.00
Dividend payout ratio (%)	―	25.7	―	―	32.8

4